Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence

Luca, Leonardo De

doi:10.1007/s10557-020-07027-4

Cited by 17 publications

(10 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…About 5% of patients with MI suffer from cardiogenic shock as a complication, with a mortality of ≥30% (5). After an episode of MI, patients remain at risk for recurrent arrhythmia, heart failure, and sudden death (6). The ability of cardiac tissue to recover after MI is affected by numerous complex cellular and molecular pathways (7).…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Silencing CircHIPK3 Sponges miR-93-5p to Inhibit the Activation of Rac1/PI3K/AKT Pathway and Improves Myocardial Infarction-Induced Cardiac Dysfunction

Yang

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The ceRNA network involving circular RNAs (circRNAs) is essential in the cardiovascular system. We investigated the underlying ceRNA network involving circHIPK3 in myocardial infarction (MI). After an MI model was established, cardiac function was verified, and myocardial tissue damage in mice with MI was evaluated. A hypoxia model of cardiomyocytes was used to simulate MI in vivo, and the expression of and targeting relationships among circHIPK3, miR-93-5p, and Rac1 were verified. The apoptosis of cardiomyocyte was identified. Gain- and loss-of-functions were performed to verify the ceRNA mechanism. The MI-modeled mice showed cardiac dysfunction and enlarged infarct size. CircHIPK3 was highly expressed in mouse and cell models of MI. Silencing circHIPK3 reduced infarct size, myocardial collagen deposition, and myocardial apoptosis rate and improved cardiac function. CircHIPK3 sponged miR-93-5p, and miR-93-5p targeted Rac1. Overexpression of miR-93-5p inhibited MI-induced cardiomyocyte injury and eliminated the harmful effect of circHIPK3. CircHIPK3 acted as ceRNA to absorb miR-93-5p, thus promoting the activation of the Rac1/PI3K/AKT pathway. We highlighted that silencing circHIPK3 can upregulate miR-93-5p and then inhibit the activation of Rac1/PI3K/Akt pathway, which can improve MI-induced cardiac dysfunction.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Silencing CircHIPK3 Sponges miR-93-5p to Inhibit the Activation of Rac1/PI3K/AKT Pathway and Improves Myocardial Infarction-Induced Cardiac Dysfunction

Yang

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Patients with HF exist in a hypercoagulable state and are at increased risk for thromboembolic events, even when in sinus rhythm ( 19 ). The presence of symptoms of HF and/or left ventricular systolic dysfunction identifies a population of MI survivors at high risk for death, reinfarction, and worsening HF ( 20 ). Reduced left ventricular ejection fraction still remains the most powerful independent predictor of sudden arrhythmic death in patients with MI.…”

Section: Discussionmentioning

confidence: 99%

CHA2DS2-VASc score for in-hospital recurrence risk stratification in patients with myocardial infarction

Hui

Zhu

Cheang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundUsing the CHA2DS2-VASc score to recognize the risk of stroke in patients with atrial fibrillation has been well-established. However, few studies have assessed whether the CHA2DS2-VASc score has a similar predictive value in recurrence after myocardial infarction (MI).MethodsWe conducted a retrospective observational cohort study of adult inpatients with MI. The CHA2DS2-VASc and modified CHA2DS2-VASc (MCHA2DS2-VASc) scores of all patients were calculated. The associations of both scores with recurrent MI were analyzed.ResultsA total of 6,700 patients with MI (60.0 ± 11.1 years, 77.2% men) were enrolled, and 759 (11.3%) presented a definite recurrence during hospitalization. After multivariable adjustment by logistic regression in patients with MI, the CHA2DS2-VASc and MCHA2DS2-VASc scores were independently associated with recurrence. The MCHA2DS2-VASc score showed a better predictive value for risk of recurrence than that of CHA2DS2-VASc in overall [area under the receiver operating characteristic curve (AUC) 0.757 vs. 0.676] or male patients (AUC 0.759 vs. 0.708). MCHA2DS2-VASc was superior to CHA2DS2-VASc for identifying “truly high-risk” patients with MI, regardless of overall patients or sex-specific subgroups. The two scores had a similar focus on the identification of “low-risk” patients in overall or women, but not in men.ConclusionThe CHA2DS2-VASc and MCHA2DS2-VASc scores for predicting recurrence are validated in patients with MI. However, MCHA2DS2-VASc could be more helpful to secondary prevention than CHA2DS2-VASc after MI, especially in men. The superiority of MCHA2DS2-VASc compared with CHA2DS2-VASc in women is just more discriminatory for “truly high-risk” patients.

show abstract

“…The effects of non-antiplatelet drugs in the post-MI set-ting are critically influenced by other pathological conditions that may frequently coexist. Among these, left ventricular systolic dysfunction confers a much higher risk of re-MI and drugs such as beta-blockers and angiotensin-converting enzyme inhibitors can dramatically improve outcomes after ACS, including re-MI [83].…”

Section: Pharmacological Strategies To Reduce Re-mimentioning

confidence: 99%

Current management and prognosis of patients with recurrent myocardial infarction

Luca¹,

Paolucci²,

Nusca³

et al. 2021

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Recurrent myocardial infarction (re-MI) is a common event following acute coronary syndrome (ACS), especially during the first year. According to epidemiological studies, patients who experience re-MI are at higher risk of all-cause cardiovascular events and mortality. The cornerstones of re-MI prevention include complete functional coronary revascularization, effective dual antiplatelet therapy and secondary prevention strategies. Notwithstanding this, some controversy still exists on the definition and management of re-MI, and no dedicated studies have been designed or conducted so far in this setting. We here provide an overview of epidemiological and prognostic data on ACS patients experiencing re-MI, along with current available treatment and preventive options.

show abstract

Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence

Cited by 17 publications

References 89 publications

RETRACTED: Silencing CircHIPK3 Sponges miR-93-5p to Inhibit the Activation of Rac1/PI3K/AKT Pathway and Improves Myocardial Infarction-Induced Cardiac Dysfunction

RETRACTED: Silencing CircHIPK3 Sponges miR-93-5p to Inhibit the Activation of Rac1/PI3K/AKT Pathway and Improves Myocardial Infarction-Induced Cardiac Dysfunction

CHA2DS2-VASc score for in-hospital recurrence risk stratification in patients with myocardial infarction

Current management and prognosis of patients with recurrent myocardial infarction

Contact Info

Product

Resources

About